The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease
- PMID: 10895397
- DOI: 10.1097/00002826-200005000-00003
The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease
Abstract
Patients with Parkinson's Disease (PD) have a variable response to tolcapone, a catechol-O-methyltransferase (COMT) inhibitor. In addition, a subset of patients develop severe diarrhea as a side effect. Two codominant alleles for the COMT gene exist, coding for low and high activity, resulting in low-, medium-, and high-activity genotypes. This study investigates the relationship between this variation in genotype and clinical effects in patients with PD taking tolcapone. To investigate the relationship between COMT polymorphism and clinical response, 24 patients who completed tolcapone clinical trials provided blood samples for COMT genotype analysis. Change in levodopa dose and United Parkinson Disease Rating Scale (UPDRS) Part III (motor subscale) were analyzed at baseline, at 1-2 weeks, and 6 months after initiation of tolcapone. Genotype analysis was performed on seven patients who had diarrhea as a side effect. There was no significant correlation between genotype and improvement in UPDRS score (p = 0.29) according to a linear models approach that adjusted for the subject's severity of PD, tolcapone dose (either 100 or 200 mg three times daily) and initial differences in baseline scores. No significant difference was seen in change in daily levodopa intake and genotype. There was also no relation between diarrhea and COMT genotype. These results indicate that, in the treatment of Parkinson's disease, COMT genotype is not a major contributor to the clinical response to tolcapone.
Similar articles
-
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD004554. doi: 10.1002/14651858.CD004554.pub2. Cochrane Database Syst Rev. 2004. PMID: 15495119 Free PMC article. Review.
-
COMT inhibition in the treatment of Parkinson's disease.J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. doi: 10.1007/pl00007743. J Neurol. 1998. PMID: 9808337 Review.
-
Extending levodopa action: COMT inhibition.Neurology. 1998 Jun;50(6 Suppl 6):S27-32; discussion S44-8. doi: 10.1212/wnl.50.6_suppl_6.s27. Neurology. 1998. PMID: 9633684 Review.
-
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.Neurology. 1998 May;50(5 Suppl 5):S39-45. doi: 10.1212/wnl.50.5_suppl_5.s39. Neurology. 1998. PMID: 9591521 Clinical Trial.
-
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.J Neural Transm (Vienna). 1997;104(2-3):229-36. doi: 10.1007/BF01273183. J Neural Transm (Vienna). 1997. PMID: 9203084 Clinical Trial.
Cited by
-
Adverse event profiles of adjuvant treatment with opicapone in Parkinson's disease: A systematic review and meta-analysis.Front Pharmacol. 2022 Nov 24;13:1042992. doi: 10.3389/fphar.2022.1042992. eCollection 2022. Front Pharmacol. 2022. PMID: 36506576 Free PMC article.
-
A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?Int J Mol Sci. 2021 Jul 5;22(13):7213. doi: 10.3390/ijms22137213. Int J Mol Sci. 2021. PMID: 34281267 Free PMC article.
-
Tolcapone Treatment for Cognitive and Behavioral Symptoms in Behavioral Variant Frontotemporal Dementia: A Placebo-Controlled Crossover Study.J Alzheimers Dis. 2020;75(4):1391-1403. doi: 10.3233/JAD-191265. J Alzheimers Dis. 2020. PMID: 32444540 Free PMC article. Clinical Trial.
-
Pharmacogenetics of Parkinson's Disease in Clinical Practice.Mov Disord Clin Pract. 2016 Nov 1;4(2):173-180. doi: 10.1002/mdc3.12444. eCollection 2017 Mar-Apr. Mov Disord Clin Pract. 2016. PMID: 30363349 Free PMC article. Review.
-
A Multi-scale Computational Platform to Mechanistically Assess the Effect of Genetic Variation on Drug Responses in Human Erythrocyte Metabolism.PLoS Comput Biol. 2016 Jul 28;12(7):e1005039. doi: 10.1371/journal.pcbi.1005039. eCollection 2016 Jul. PLoS Comput Biol. 2016. PMID: 27467583 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous